Y Intercept Hong Kong Ltd Acquires New Holdings in Kyverna Therapeutics, Inc. $KYTX

Y Intercept Hong Kong Ltd bought a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 114,841 shares of the company’s stock, valued at approximately $991,000. Y Intercept Hong Kong Ltd owned about 0.19% of Kyverna Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in KYTX. AIGH Capital Management LLC acquired a new position in Kyverna Therapeutics during the 4th quarter worth $14,100,000. RFG Advisory LLC acquired a new position in shares of Kyverna Therapeutics in the 4th quarter valued at $4,185,000. Simplify Asset Management Inc. acquired a new position in Kyverna Therapeutics in the fourth quarter worth about $1,808,000. Maven Securities LTD bought a new position in shares of Kyverna Therapeutics during the 4th quarter worth approximately $1,376,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at $1,833,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

KYTX stock traded down $1.33 during trading on Friday, reaching $8.48. 1,991,001 shares of the company were exchanged, compared to its average volume of 1,200,396. The company has a market capitalization of $515.50 million, a price-to-earnings ratio of -2.59 and a beta of 1.87. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The company has a 50-day moving average of $8.72 and a two-hundred day moving average of $8.65. Kyverna Therapeutics, Inc. has a twelve month low of $2.80 and a twelve month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. As a group, equities analysts predict that Kyverna Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on KYTX. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. JPMorgan Chase & Co. cut their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.